Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 15,138 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Completed Phase 2 Interventional

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00571675
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
AT-101, prednisone and docetaxel, placebo, prednisone and docetaxel
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Colorado Springs, Colorado • New Port Richey, Florida • Ocoee, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2010 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

NCT03897075
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis
Interventions
Tildrakizumab, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Encinitas, California • Fountain Valley, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

NCT03340675
View directory record Official record
Conditions
Duchenne Muscular Dystrophy Cardiomyopathy, Cardiomyopathy, Dilated
Interventions
Ifetroban, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
7 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 2 Interventional

Study of Motilitone to Treat Functional Dyspepsia

NCT02365701
View directory record Official record
Conditions
Dyspepsia
Interventions
Motilitone 30mg, Placebo
Drug
Lead sponsor
Dong-A ST Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

NCT01853046
View directory record Official record
Conditions
Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

NCT04629170
View directory record Official record
Conditions
Healthy, Enteric Hyperoxaluria
Interventions
SYNB8802, Placebo
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 74 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Tucson, Arizona • Tampa, Florida • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 29, 2026, 5:05 AM EDT
Recruiting Phase 2 Interventional

Oxytocin Effects on Bone in Children With Autism Spectrum Disorder

NCT05754073
View directory record Official record
Conditions
Autism Spectrum Disorder, Bone Health
Interventions
1. Intranasal oxytocin spray, 2. Intranasal placebo spray, 3. Intranasal Oxytocin spray
Drug
Lead sponsor
Elizabeth Austen Lawson
Other
Eligibility
6 Years to 18 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of CDX-0159

NCT04146129
View directory record Official record
Conditions
Healthy Subjects
Interventions
CDX-0159, Normal saline
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 29, 2026, 5:05 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

NCT07266402
View directory record Official record
Conditions
Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
Interventions
Barzolvolimab, Matching Placebo
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 29, 2026, 5:05 AM EDT
Active, not recruiting Phase 2 Interventional

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT04514653
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
Ranibizumab, ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Local Steroid, Topical Steroid, ABBV-RGX-314 Dose 4
Biological · Genetic · Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Results available

A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01309737
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo/CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
44
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Bakersfield, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 29, 2026, 5:05 AM EDT
Terminated Phase 1Phase 2 Interventional

L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)

NCT04852172
View directory record Official record
Conditions
Acute Vaso Occlusive Crisis (VOC)
Interventions
L-citrulline, D5 1/2NS
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Analgesic Efficacy & Safety of Intravenous (IV) Acetaminophen Versus Placebo for the Treatment of Postop Pain

NCT00564486
View directory record Official record
Conditions
Pain
Interventions
IV Placebo, IV Acetaminophen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 80 Years
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
17
States / cities
Sheffield, Alabama • Phoenix, Arizona • Arcadia, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

NCT04771273
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Survodutide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
36
States / cities
Huntsville, Alabama • Coronado, California • Huntington Park, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis

NCT02933866
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
DSXS topical, Vehicle topical
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
371 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 2 Interventional

Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

NCT00807053
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Ciclesonide HFA, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
31
States / cities
Mission Viejo, California • Orange, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 29, 2026, 5:05 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

NCT06693895
View directory record Official record
Conditions
Chickenpox
Interventions
Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Huntington Park, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 2 Interventional

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

NCT03307577
View directory record Official record
Conditions
Acne Vulgaris
Interventions
UHE-101 Cream, Vehicle Cream
Drug · Other
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 2 Interventional

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia

NCT00378131
View directory record Official record
Conditions
Cancer Cachexia
Interventions
RC-1291, placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
17
States / cities
Glendale, Arizona • Encinitas, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2013 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

NCT03595553
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ridinilazole, Vancomycin
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
49
States / cities
Birmingham, Alabama • Sun City, Arizona • Los Angeles, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain

NCT01619839
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
NKTR-181, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
34
States / cities
Mobile, Alabama • Tucson, Arizona • Garden Grove, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia

NCT02164981
View directory record Official record
Conditions
Schizophrenia
Interventions
sodium nitroprusside, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Glen Oaks, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 29, 2026, 5:05 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

NCT05164341
View directory record Official record
Conditions
Partial Lipodystrophy
Interventions
metreleptin, Placebo
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
12 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Sacramento, California • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 29, 2026, 5:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

NCT02748694
View directory record Official record
Conditions
Healthy Volunteers, Schizophrenia
Interventions
TAK-041, TAK-041 Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 29, 2026, 5:05 AM EDT